Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 198 entries
View as:

A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05442138 Org: User:
Start: 08/31/22 End: 06/30/24 Due: 06/30/25

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Phase: N/A Priority: Normal
NCT ID: NCT06370416 Org: User:
Start: 04/30/24 End: 12/31/25 Due: 12/31/26

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06427213 Org: User:
Start: 05/20/24 End: 12/30/29 Due: 12/30/30

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04675866 Org: User:
Start: 08/17/20 End: 12/31/23 Due: 12/31/24

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05313906 Org: User:
Start: 05/07/22 End: 04/30/24 Due: 04/30/25

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05647330 Org: User:
Start: 12/15/22 End: 10/01/25 Due: 10/01/26

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT05583383 Org: User:
Start: 03/31/22 End: 03/31/25 Due: 03/31/26

Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT07037576 Org: User:
Start: 05/20/25 End: 03/30/28 Due: 03/30/29

Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT07037537 Org: User:
Start: 10/30/24 End: 11/30/26 Due: 11/30/27

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04433156 Org: User:
Start: 04/22/20 End: 04/22/25 Due: 04/22/26

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04668365 Org: User:
Start: 12/25/20 End: 12/25/25 Due: 12/25/26

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06945705 Org: User:
Start: 04/02/25 End: 10/02/28 Due: 10/02/29

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT05598229 Org: User:
Start: 12/28/24 End: 12/30/25 Due: 12/30/26

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04229849 Org: User:
Start: 01/31/20 End: 01/31/22 Due: 01/31/23

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03954756 Org: User:
Start: 06/01/19 End: 06/01/21 Due: 06/01/22

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04213898 Org: User:
Start: 01/31/20 End: 01/31/23 Due: 01/31/24

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05013697 Org: User:
Start: 09/30/21 End: 07/31/23 Due: 07/31/24

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)

Phase: N/A Priority: Normal
NCT ID: NCT04138212 Org: User:
Start: 10/22/19 End: 12/21/28 Due: 12/21/29

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05617859 Org: User:
Start: 04/30/23 End: 12/31/26 Due: 12/31/27

Application of Antiosteoporosis Therapy in Osteolysis

Phase: N/A Priority: Normal
NCT ID: NCT05617846 Org: User:
Start: 12/28/24 End: 11/30/32 Due: 11/30/33

Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05468970 Org: User:
Start: 08/03/22 End: 07/31/32 Due: 07/31/33

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06293014 Org: User:
Start: 02/23/24 End: 11/28/26 Due: 11/28/27

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06546150 Org: User:
Start: 08/01/24 End: 04/01/27 Due: 04/01/28

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03101709 Org: User:
Start: 08/31/16 End: 07/31/19 Due: 07/31/20

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05276167 Org: User:
Start: 06/06/22 End: 12/31/25 Due: 12/31/26